AmacaThera doses first in-human study to evaluate AMT-143 for non-opioid treatment of post-operative pain

AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company’s lead asset in non-opioid acute pain management. AMT-143 is a local slow-release non-opioid local anesthetic that would leverage the AmacaGel platform to provide long-acting post-operative pain relief and is the first therapeutic product formulated to be delivered via AmacaGel, AmacaThera’s patented technology platform.

AmacaThera is an OBIO® member, an alumnus of all OBIO® programs, and presented at the OBIO® Investment Summit.